ARTICLE | Company News
Vytacera Pharma Inc., University of Minnesota deal
February 13, 2012 8:00 AM UTC
The university granted newco Vytacera exclusive, worldwide rights to develop and commercialize cyanide poisoning treatment Sulfanegen. The prodrug of 3-mercaptopyruvate (3-MCP) is being developed unde...